Profile of patients treated with intravitreal anti-vascular endothelial growth factor injections in Bhutan: a 3-year national survey

Purpose: Ocular vascular diseases are common causes of visual impairment and blindness, for which intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the first-line therapy. Current study describes the profile of patients receiving intravitreal anti-VEGF injections in Bhutan. This is the first study of its kind to inform the national health policy. Methods: For this retrospective study, we reviewed the surgical registers of the vitreoretinal unit across Bhutan over three years. Patient demography, clinical findings, diagnostic tests performed, and diagnoses or indications for intravitreal anti-VEGF injections were logged. A descriptive analysis was performed. Results: A total of 381 patients received intravitreal anti-VEGF injections in the operating theatres as mandated by the national guidelines. The majority of patients were males (230, 60.4%). The mean age was 65.2 {+/-} 13.5 years, ranging from 13 to 90 years, and a median of 69 years. Majority of the treated eyes (117, 30.7%) had BCVA <3/60 to light perception (PL), and another 51 eyes (13.4%) had < 6/60 to 3/60. The most common indication for anti-VEGF injection was neovascular AMD (168 cases, 42.2%), followed by retinal vein occlusion (132 cases, 34.6%), diabetic macular oedema and retinopathy (50 cases, 13.1%), and myopic choroidal neovascular membrane (11 cases, 0.03%). Conclusions: Bhutan faces both economic and geographic challenges, on top of limited human resources for managing vitreoretinal diseases. With an ever-increasing load of vitreoretinal diseases, and systemic diseases like diabetes and hypertension, there is a need to improve vitreoretinal services. Regular vitreoretinal services are provided only at the national referral hospital located in the north-west. For successful management, an effective community screening program, right referrals, and proper transport facilities must go hand-in-hand, and or extend regular vitreoretinal services to regional referral hospitals.

3 23 community screening program, right referrals, and proper transport facilities must go hand-24 in-hand, and or extend regular vitreoretinal services to regional referral hospitals.
. CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283009 doi: medRxiv preprint 5 53 B, placental growth factor-1 (PlGF-1) and placental growth factor-2 (PlGF-2) (14, 15). 54 Faricimab is a new and the first bispecific monoclonal antibody for intravitreal use 55 neutralising both VEGF and angiopoietin-2/tie-2/ pathway(16). Due to the prolonged activity, 56 faricimab allows extended intervals between injections of up to three or four months in 57 nAMD and DMO patients, which can be a significant benefit for patients and are an 58 alternative to implanted drug delivery systems (17, 18). The aim of the current study was to 59 report on the profile of patients treated with intravitreal anti-VEGFs injections for 60 ophthalmological diseases in Bhutan. Since this is the first study of this kind in the country is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283009 doi: medRxiv preprint 6 77 when the treatment is provided there. The sites for the current study included JDW national 78 referral hospital (in the main), and ERRH and CRRH.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283009 doi: medRxiv preprint 100 For the current study, the patient register maintained in the vitreoretinal operational theatre 101 was reviewed for the data collection. The data collected included demographic information 102 such as age and gender, residential settings, BCVA, diagnostic tests performed, and diagnosis 103 or indications for anti-VEGF injections.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283009 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022.

257
This study is limited by being a retrospective study and a small number of study subjects.
258 We did not have visual acuity at presentation for 85 cases (22.3%). Being a cross-sectional . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 266 So regular services need to be expanded to the eastern and central regional referral hospitals.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022.  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 5, 2022. ; https://doi.org/10.1101/2022.12.01.22283009 doi: medRxiv preprint